Validation of the Musculoskeletal Health Questionnaire in inflammatory arthritis:a psychometric evaluation by Norton, Sam et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1093/rheumatology/key240
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Norton, S., Ellis, B., Santana Suárez, B., Schwank, S., Fitzpatrick, R., Price, A., & Galloway, J. (2018). Validation
of the Musculoskeletal Health Questionnaire in inflammatory arthritis: a psychometric evaluation. Rheumatology.
https://doi.org/10.1093/rheumatology/key240
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
1 
 
Validation of the Musculoskeletal Health Questionnaire (MSK-HQ) in inflammatory 
arthritis: a psychometric evaluation 
 
Sam Norton,1,2 Benjamin Ellis,3 Beatriz Santana Suárez,1 Samana Schwank,1 Ray Fitzpatrick,4 Andrew 
Price,5 James Galloway1 
 
1. Academic Rheumatology, Faculty of Life Sciences and Medicine, King’s College London, London, 
United Kingdom 
2. Psychology Department, Institute of Psychiatry, Psychology & Neuroscience, King’s College 
London, London, United Kingdom 
3. Imperial College Healthcare NHS Trust, London, United Kingdom  
4. Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom 
5. Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, Botnar 
Research Centre, University of Oxford, Oxford, United Kingdom 
 
Corresponding author:  
James Galloway, Academic Rheumatology, King’s College London. james.galloway@kcl.ac.uk  
 
 
 
  
2 
 
Abstract 
Objectives: The Musculoskeletal Health Questionnaire (MSK-HQ) is a recently developed Patient 
Reported Outcome Measures (PROM) for use across patients with different musculoskeletal 
conditions. This study provides a validation of the MSK-HQ examining construct validity and 
reliability in inflammatory arthritis. 
Methods: 287 adults with inflammatory arthritis completed the MSK-HQ and other PROMs at 
baseline and again after three-months. Construct validity was assessed using item response theory 
(IRT) methods. Concurrent validity of the MSK-HQ was considered in relation to the Health 
Assessment Questionnaire (HAQ) and EQ5D in all patients, as well as the Rheumatoid Arthritis (RA) 
Impact of Disease (RAID), Psoriatic Arthritis (PsA) Impact of Disease (PsAID) scales, and Ankylosing 
Spondylitis (AS) Quality of Life Questionnaire (ASQoL) in disease subtypes. 
Results: The MSK-HQ was approximately normally distributed with no evidence of floor or ceiling-
effects. A unidimensional structure was confirmed though two items were less weakly related to the 
latent musculoskeletal health variable, providing some evidence of multidimensionality. Reliability 
across the range of responses was high (α=0.93). The total scale score correlated highly with the 
HAQ (r=-0.81), EQ5D index (r=0.80) and EQ5D visual analogue scale (r=0.60) in all patients, RAID in 
RA patients (r=-0.88), PsAID in PsA patients (r=-0.88), and ASQoL in AS patients (r=-0.86). Test-retest 
reliability over 3 months was high (rICC=0.73).  
Conclusions: This study provides evidence for the validity and reliability of a new musculoskeletal 
health PROM in people with inflammatory arthritis. The major advantage of the MSK-HQ is that it is 
not disease specific and has high content validity in rheumatological conditions. The MSK-HQ score 
will be of value in clinical rheumatology practice, providing a measure which can be used across 
disease areas. 
Keywords 
Quality of life; outcomes measures; inflammatory arthritis 
Key messages 
 The MSK-HQ is a valid and reliable measure of musculoskeletal health related quality of life. 
 It is not disease specific and can be used across inflammatory arthritis subtypes. 
 A shortened version, excluding two items assessing understanding and self-efficacy, is 
potentially optimal.  
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Introduction 
Collecting patient views about their own health using Patient Reported Outcome Measures (PROMs) 
is central to evaluating clinical care in routine practice and research.[1,2] For instance, PROMS can 
act as a catalyst for organisational change by improving standards, as evidenced by the NHS England 
National PROMs Programme.[3] A large number of PROMs currently exist, many addressing aspects 
of musculoskeletal health. Generic PROMs assessing health related quality of life (e.g. 36-Item Short 
Form Health Survey [SF-36], EuroQol-5D [EQ-5D]) allow for broad comparisons to be made across 
health conditions. However, generic instruments may have limited sensitivity to compare between 
musculoskeletal conditions since they do not necessarily capture constructs pertinent to 
musculoskeletal health.[4] Within rheumatology, PROMs assessing musculoskeletal health related 
quality of life have, in general, been developed specific to individual diseases (e.g. Rheumatoid 
Arthritis Impact of Disease (RAID), Psoriatic Arthritis Impact of Disease (PsAID); until recently there 
was no musculoskeletal health PROM validated across the spectrum of musculoskeletal conditions. 
The Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) is a recently developed 
PROM assessing musculoskeletal health related quality of life for use by patients with different 
musculoskeletal conditions, across a range of settings.[5] This scale incorporates the assessment of 
physical symptoms such as pain and fatigue, plus the impact of disease on psychological well-being.  
The initial development of the MSK-HQ included a detailed scoping exercise and qualitative 
development phase involving both patients and clinicians.[5] In a sample of 570 people with 
osteoarthritis, the MSK-HQ was demonstrated to have good internal consistency between items, as 
well as high test-retest reliability and convergent validity compared to other measures of 
musculoskeletal health used in osteoarthritis populations. While initial findings are promising, 
additional validation studies are needed to confirm the utility of the MSK-HQ as an outcome 
measure for more widespread use.[6] Specifically, though content (e.g. face) validity for the MSK-HQ 
is high, further research is needed to examine the construct validity of the scale, by confirming the 
assumed unidimensional structure, and its reliability in other musculoskeletal conditions. 
The aim of the present study was to examine the construct validity and test-retest reliability of the 
MSK-HQ in people with inflammatory arthritis.  
Methods 
Sample 
Patients were recruited from six centres between September 2015 and July 2016. Eligibility criteria 
were adults with an established diagnosis of inflammatory arthritis (rheumatoid arthritis (RA), 
undifferentiated inflammatory arthritis (UIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS)) 
who were initiating a new synthetic or biologic anti-rheumatic medication as part of routine care. 
Follow up data were collected by post at three months, following baseline visit.  
Outcomes measures 
MSK-HQ 
The MSK-HQ consists of 14 items relating to facets of musculoskeletal health including pain, fatigue, 
physical function, symptom interference, sleep, self-efficacy and psychological well-being.[5] 
Respondents rate how much their musculoskeletal condition in the previous two weeks has affected 
each facet using a five-point ordinal scale from “not at all” to “extremely”, respectively scored from 
four to zero. Items 12, relating to understanding, and 13, relating to self-efficacy, have their 
response scale reversed where “not at all” is scored zero. Items are summed to generate a total 
score with a range from 0 to 56, where higher scores indicate better musculoskeletal health status. A 
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fifteenth item assessing physical activity in the past week is not included in the total score and was 
therefore not considered in the current analysis. Previous analysis in non-inflammatory 
musculoskeletal disease has demonstrated good reliability (Cronbach's α = 0.88, test-retest = .84).[5]  
Sample copies of the MSK-HQ and a license for use can be obtained at 
https://innovation.ox.ac.uk/clinical-outcomes/patient-reported-outcome-measures 
Other PROMs 
All participants completed the Health Assessment Questionnaire (HAQ),[7] which assesses 
functioning across eight domains. This is the most widely used measure of functional ability in 
musculoskeletal conditions and 20 items assessing the difficulty of completing specific daily activities 
across eight domains. A further 18 items with a binary response format relating to the use of 
assistive devices or help from others. Scale scores range between 0 and 3, increasing in increments 
of 0.125, where higher scores indicate worse functional limitation.  
All participants also completed the EQ5D-5L a generic measure of health related quality of life. The 
version used includes response categories with five levels of severity for each of five items assessing 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses to these 
items are combined against value sets to generate an index value (utility) that reflects the 
preferences compared to other responses. An additional item asks respondents to rate the health on 
a 0 to 100 visual analogue scale (VAS).    
Patients with RA and UIA completed the RAID questionnaire.[8] This scale consists of seven items 
scored between 0 and 10. The total score is calculated as a weighted mean across all items where 
weights are based on patient rating of importance. The scale score ranges between 0 and 10, where 
higher scores indicate greater impact of disease. A minimum clinically important difference (MCID) 
of an absolute change of 3 has been recommended.[9] 
Patients with PsA completed the nine item version of the PsAID.[10] This scale consists of nine items 
scored between 0 and 10. As with the RAID, the total score is calculated as a weighted mean across 
all items providing a scale score ranging between 0 and 10, where higher scores indicate greater 
impact of disease. An MCID of 3 has also been proposed. 
Patients with AS completed the Ankylosing Spondylitis Quality of Life questionnaire (ASQoL) [11] and 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).[12] 
Data analysis 
Construct validity was assessed using item response theory (IRT) methods.[13] These approaches 
assume responses to the set of items forming the scale are due to a single underlying latent variable 
(e.g. musculoskeletal health). Therefore, unidimensionality was initially examined using principal 
components analysis with parallel analysis to determine the number of underlying latent variable 
explaining more than chance variance in item response correlations.[14] Since the response scale is 
ordinal, the polychoric method was used to estimate the correlation between items.[15] After 
examining unidimensionality, IRT methods explored the functioning of individual items. A graded 
response model for ordinal items was estimated.[16] Preliminary analyses confirmed a graded 
response model provided a better fit to the data than a partial credit or generalised partial credit 
models. The graded response model estimates a discrimination parameter for each item and a 
difficulty parameter per response category for each item. Respectively, these parameters represent 
the strength of the association (correlation) between the item and the level of the latent 
musculoskeletal health variable being assessed, and the level of the latent variable where an 
individual is estimated to have 50% probability of responding positively to the response category for 
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the item. Items with low discrimination that do not correlate highly with the latent musculoskeletal 
health variable are considered poor indicators that should not be included in the scale.[14] Here we 
use the rule of thumb from the factor analytic literature that items that correlate less than 0.6 are 
weak. 
To test the assumption that scores on the MSK-HQ are comparable across disease groups, 
differential item functioning (DIF) was assessed using ordinal logistic regression models. This 
approach, which is a reparameterisation of the graded response model,[17] sequentially compares 
models for differences in both difficulty and discrimination parameters (uniform and non-uniform 
DIF). A false discovery rate correction was applied to control for multiple testing. 
Reliability, representing the precision with which the scale score assesses an individuals’ true level of 
musculoskeletal health, was assessed using four methods. Using the baseline assessment the 
association between items was summarised using Cronbach’s estimate of internal consistency α. 
Measurement precision across the range of musculoskeletal health was further assessed by 
examining the test information function from the graded response model. A change greater than 
measurement error was computed based on the reliable change index,[18] which uses alpha and the 
baseline standard deviation to determine the 95% interval where changes that may be due to 
chance alone would lie. Test-retest reliability for the scale score was assessed using the intra-class 
correlation coefficient and for individual items using Kendall’s concordance coefficient, a descriptive 
measure indicating agreement between ordinal rankings. All analyses were conducted in Stata 14.2.  
Results 
The sample included people with RA (208, 72%), PsA (45, 16%), AS (22, 8%) and UIA (12, 4%). All 
patients were included in the main analyses; disease specific analyses were performed for RA and 
PsA only. Of the 287 providing data at baseline, 178 (62%) provided data again after three weeks to 
allow test-retest reliability to be assessed. Baseline information is provided in Table 1. 
Information about the functioning of the 14 items is given in the supplementary data. High 
acceptability was indicated by low levels of missing data per item (range 0.0% to 1.7%). All items 
showed responses across the range of categories with positive inter-item correlations ranging from 
weak to strong (range 0.07 to 0.82, mean inter-item correlation 0.57), though the majority of 
correlations were strong (i.e. r>0.5). 
The distribution of the MSK-HQ total score was approximately normally distributed with participants 
scoring across the entire range from 0 to 56. No floor or ceiling effect was observed. RA patients had 
the most favourable MSK-HQ total scores, with a mean score of 26.8 (SD=11.9) compared to 24.6 
(13.1) for PsA patients and 23.2 (8.6) for those with other inflammatory arthritis conditions. 
Structural validity 
The first principal component of the item correlation matrix explained 62.8% of the total variance, 
indicating that a single underlying latent musculoskeletal health variable explained the majority of 
the variability in item responses. However, parallel analysis suggested the pattern of correlations 
between item responses was likely to result from two underlying latent variables. Specifically, an 
additional minor latent variable explained a further 9.5% of the item variance, which was greater 
than expected by chance. Examining inter-item and item-total correlations (supplementary 
materials) revealed that items 12 “understanding” and 13 “self-efficacy” were less related to overall 
musculoskeletal quality of life compared to other items and potentially reflect a separate construct. 
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The IRT graded response model confirmed this observation. Figure 1 plots the item characteristic 
curves for each response category separately for each item. These plots show the probability that 
each response category is endorsed given an individuals’ level of the latent musculoskeletal health 
variable. The gradient of the item characteristic curve is defined by the items discrimination 
parameter, and the point at which the crosses 0.5 by its difficulty parameter. Transforming the 
discrimination parameters to the more familiar correlation metric indicates that the correlation 
between the response to each item and the latent musculoskeletal health variable was between 
r=0.75 and 0.91 for all variables, except for understanding (r=0.19) and self-efficacy (r=0.52). Further 
analyses considers the total scale score across all items and a reduced scale score excluding these 
two items. 
Additional analysis considered differential item functioning by inflammatory arthritis subtype for 
those with RA and PsA. Due to low numbers those with AS and UIA were not included in this 
analysis. For the total score across all items, item 9 “sleep” (χ2(2)=11.37, p=0.003) and item 14 
“overall impact” (χ2(2)=7.79, p=0.020) demonstrated non-uniform differential item functioning 
between those with RA and PsA. This was also observed for the reduced scale score. In both 
instances, responses to the items were better at discriminating between levels of musculoskeletal 
health in the PsA group than the RA group. The magnitude of bias for the “overall impact” item was 
small but more considerable for the “sleep” item. 
Concurrent validity 
The MSK-HQ was compared against five instruments assessing similar constructs as a test of 
construct validity (Figure 3). A strong positive correlation was observed with the EQ5D Index (n=285, 
r=0.80) and VAS (n=285, r=0.60) for all patients. Strong negative correlations were observed with the 
HAQ for all participants (n=284, r=-0.81), the RAID for those with RA or UIA (n=218, r=-0.88), the 
PsAID for those with PsA (n=43, r=-0.88), and the ASQoL for those with AS (n=22, r=-0.86). This 
supports the assumption that the MSK-HQ total score measures a highly related latent variable to 
these measures.  
There was some indication of non-linearity in the relationship between the MSK-HQ with the HAQ 
and EQ5D Index, which is suggestive of the HAQ and EQ5D Index being more sensitive at 
differentiating between those with extremely poor musculoskeletal health. However, the MSK-HQ 
performs better in differentiating between those with better function since there is no floor effect 
observed, as is present for HAQ. 
Reliability 
Reliability was high for the both the total scale score including all items and the reduced scale score 
excluding items 12 and 13: α=0.93 and α=0.95, respectively. The IRT construct of information is 
related to reliability and has the advantage that measurement precision can be assessed at different 
points across the range of the latent variable. The test information curve (Figure 2) demonstrates 
that reliability was high (>0.8) between around 3 standard deviations below and above the mean of 
the latent musculoskeletal health variable. Converted to the metric of the MSK-HQ, reliability is 
above 0.8 for people scoring between approximately 3 and 54, where the range 0 to 56. A reliable 
change above measurement error was estimated to be a change of 9 points or more for the full 
scale, and 7 points of more for the reduced scale, given its higher reliability and reduced range. 
Test-retest reliability 
Data at follow up were provide by 178 (67.9%) participants with RA, PsA or UIA. Of these, 143 
(80.3%) had stable symptoms as indicated by differences in either RAID or PsAID scores less than the 
minimum clinically important difference. Within those with stable symptoms, the MSK-HQ total 
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score test-retest reliability had an intraclass correlation coefficient rICC=0.73 (95% CI: 0.67 to 0.81) 
and for the reduced scale score rICC=0.75 (95% CI: 0.65 to 0.80). Examining test-retest agreement at 
the item level, Kendall’s concordance coefficient ranged from 0.54 to 0.81 across all items and was 
greater than 0.7 for all items except 12 “understanding” and 13 “self-efficacy”. 
Discussion 
This study has confirmed that the MSK-HQ performs well as a PROM for assessing musculoskeletal 
health related quality of life within an inflammatory arthritis cohort, with acceptable psychometric 
properties. The MSK-HQ is simple to administer and has good acceptability with patients. The tool 
includes seven domains including pain, fatigue, physical function, symptom interference, sleep, self-
efficacy and psychological well-being. These domains were selected through a process of extensive 
consultation with patients to ensure the measure captured items that matter most [5]. The total 
score is reached by summing up each individual item, making the tool also simple for clinicians to 
use. The result ranges from 0 (worst musculoskeletal health) to 56 (best). We estimate a statistically 
reliable change, where measurement error can be ruled out for 95% of cases, to be a change in the 
full scale score of 9 points or higher.  
The MSK-HQ was highly related to other measures of musculoskeletal health in the sample, with 
correlations with the HAQ, EQ5D index, RAID PsAID, ASQoL all greater than 0.8. Compared to the 
HAQ, the MSK-HQ will perform better at differentiating between those where the impact of disease 
is relatively mild due to the lack of floor effect. Furthermore, while there have been attempts to 
improve the validity of the HAQ as a tool for capturing musculoskeletal health,[19,20] the HAQ 
predominantly considers functional limitation related to the upper limbs and as such assesses only 
one important facet of musculoskeletal health.  
Given the high degree of content overlap relating to both the RAID and PsAID, the high correlations 
with the MSK-HQ and these instruments are not surprising. The RAID and PsAID  perform well 
psychometrically,[8,10] and there is little reason to recommend the use of the MSK-HQ over these 
two recently and well developed PROMs in disease specific studies. In our view, each will adequately 
assess health related quality of life; defined by the impact of inflammatory arthritis on a range of 
lower level constructs including physical function, pain, fatigue sleep, and psychological well-being. 
The advantage of the MSK-HQ, over the RAID and PsAID, is that it can potentially be used as a 
universal questionnaire across musculoskeletal conditions. This not only allows for the comparison 
of disease burden across conditions but reduces the logistical burden on clinicians and researchers 
having to manage multiple PROMs; reducing the risk that incorrect PROMs are completed. Although 
the MSK-HQ, RAID and PsAID assess a broad health related quality of life construct, they are still 
specific to populations with a musculoskeletal disorder. In situations where health economic analysis 
requires the calculation of utilities (e.g. for comparison across conditions) generic health related 
quality of life measures, such as the EQ5D, will also need to be administered. 
The psychometric properties of the MSK-HQ are important to consider. Whilst the overall analysis 
supports the pragmatic use of the total score as a single measure of musculoskeletal health, 
interrogation of the measure reveals some interesting, if not unexpected, results. Two of the 14 
items, relating to understanding and self-efficacy (illness perception items), appear to behave 
differently to the other items: the relationship between overall musculoskeletal health and 
individual items is weaker for the illness perception items.  In particular the understanding item was 
only weakly related to musculoskeletal health, indicating that an individuals reported level of 
understanding is not particularly related to the severity of their condition. Understanding, as a 
construct, reflects something distinct from, though related to musculoskeletal health. It is likely that 
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the understanding item assesses the concept of illness coherence  from the self-regulation model of 
illness.[21] Similarly, the self-efficacy item is related to the concept of personal control within this 
theoretical framework. The self-regulation model of illness, which includes other important illness 
perceptions of consequences, chronicity, stability, and treatment control, describes the process 
whereby beliefs influence the individual’s emotional response to their illness and their coping 
behaviours, such as adherence to treatment.[22,23] In inflammatory arthritis, patient’s perceptions 
of their illness have been shown to be associated with treatment adherence, function, pain and 
mood even after controlling for underlying disease.[22,24–26]  
The relevance of these psychometric characteristics depends upon how the tool is intended to be 
used. As a measure for a clinical trial or assessing the standard of care in routine practice where a 
high degree of reliability is desired, it might be prudent to analyse the 12-items that performed best 
independently (items 1-11, & 14). When using the tool in the clinic, the impact of the two items is 
unlikely to make meaningful difference. In contrast, having insight into an individual’s illness 
perceptions has substantial clinical utility. Supporting people to develop understanding and self-
efficacy is an important goal for health services to achieve given their relationship to self-
management and outcomes. Furthermore, given the method of development of the MSK-HQ, the 
inclusion of illness perceptions highlights their importance to patients. The use of validated PROMs 
for assessing the broader range of illness perceptions alongside the MSK-HQ may provide additional 
information about the mechanisms by which the disease impacts musculoskeletal health.[27,28] 
The study must be considered alongside its limitations. The sample was predominantly RA and PsA, 
and so the conclusions across the other disease areas needs further study. We found some 
indication of differential item functioning across inflammatory arthritis subtypes. While the level 
observed is unlikely to bias comparisons between different inflammatory arthritis subtypes, it is 
difficult to draw robust inferences given the size of the sub groups. There is a clear need for further 
study with considerably larger sample sizes. In addition, while we provide some information 
potentially relevant to sensitivity to change, in terms of a change that is greater than the expected 
natural variation in scores, more robust assessment is required to determine whether such a change 
is clinically meaningful to patients. Calculation of the minimum clinically important difference may 
reveal a change that is smaller than the statistically reliable change is meaningful.  
In this study, we have provided further support for the validity and reliability of a new 
musculoskeletal health PROM in people with inflammatory arthritis. The tool compares well to 
existing PROMs, with the added advantage of lacking the floor effect of HAQ. The major advantage 
of the MSK-HQ is that it is not disease specific and has high content validity in rheumatological 
conditions. We believe that the MSK-HQ score will be of value in clinical rheumatology practice, 
providing a measure which can be used across disease areas.  
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Tables 
Table 1. Sample characteristics 
 All patients 
n=287 
RA 
n=208 
PsA 
n=45 
AS 
n=22 
UIA 
n=12 
Age, mean (SD) 55 (18) 56 (17) 52 (19) 47 (14) 58 (18) 
Female, n (%) 191 (67) 148 (71) 22 (49) 13 (59) 8 (75) 
Years since diagnosis, 
median (IQR) 
1 (0,7) 1 (0,7) 1 (0,6) 2 (0,18) 1 (0,11) 
HAQ, mean (SD) 0.80 (0.59) 0.79 (0.61) 0.82 (0.58) 0.95 (0.48) 0.55 (0.41) 
MSK-HQ, mean (SD) 27 (12) 27 (12) 25 (13) 21 (7) 29 (11) 
RA=rheumatoid arthritis; PsA=psoriatic arthritis; AS=ankylosing spondylitis; UIA=undifferentiated 
arthritis; SD=standard deviation; IQR=interquartile range; HAQ=health assessment questionnaire 
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Figures 
 
Figure 1. Test information function for the MSK-HQ 
Test information (y-axis) relates to the precision of the scale (i.e. reliability) given the level of latent 
musculoskeletal health variable (x-axis). Dashed lines indicate levels of information where reliability 
on the familiar metric (e.g. that of Chronbach’s α) is 0.8 and 0.9. Reliability is high from around 3 
standard deviations below to 3 standard deviations above the mean of the latent musculoskeletal 
health variable. 
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Figure 2. Concurrent validity of the MSK-HQ against other PROMs 
Scatterplots indicating strong negative associations between the MSK-HQ total score and scores for 
other general and disease specific patient reported outcome measures (PROMs): Health Assessment 
Questionnaire (HAQ) and EQ5D in all patients, Rheumatoid Arthritis Impact of Disease (RAID) in RA 
patients, Psoriatic Arthritis Impact of Disease (PsAID) in PsA patients, and Ankylosing Spondylitis 
Quality of Life Questionnaire (ASQoL) in AS patients. Lines are fractional polynomial regression of 
MSK-HQ on the other PROM as an indicator of potential non-linearity in the association. 
 
